Antibody-Drug Conjugate for Pediatric Gliomas

We are developing new drugs to combat brain cancer with increased effectiveness and reduced side effects. To do this, we are looking to specifically target certain proteins that are more typical of brain cancers and less common outside of tumor cells. This work aims to improve the likelihood of patient recovery as well as reduce the adverse effects and risks of current treatments. CBTN would help with this work, as it is imperative that we use patient specimens and tumoroids to characterize target protein expression in glioma tissue and to most effectively test the efficacy of the drug once it is formulated.